nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A4—Thiotepa—urinary bladder cancer	0.112	0.276	CbGbCtD
Salmeterol—CYP2C8—Fluorouracil—urinary bladder cancer	0.0898	0.221	CbGbCtD
Salmeterol—CYP3A5—Etoposide—urinary bladder cancer	0.078	0.192	CbGbCtD
Salmeterol—CYP2C8—Etoposide—urinary bladder cancer	0.075	0.185	CbGbCtD
Salmeterol—CYP3A4—Etoposide—urinary bladder cancer	0.0304	0.0749	CbGbCtD
Salmeterol—CYP3A4—Doxorubicin—urinary bladder cancer	0.0207	0.0511	CbGbCtD
Salmeterol—CYP2C8—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00228	0.0279	CbGpPWpGaD
Salmeterol—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00218	0.0267	CbGpPWpGaD
Salmeterol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00174	0.0214	CbGpPWpGaD
Salmeterol—CYP3A7—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00172	0.0211	CbGpPWpGaD
Salmeterol—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0017	0.0209	CbGpPWpGaD
Salmeterol—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00151	0.0185	CbGpPWpGaD
Salmeterol—CYP3A7—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00141	0.0173	CbGpPWpGaD
Salmeterol—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00126	0.0155	CbGpPWpGaD
Salmeterol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00126	0.0154	CbGpPWpGaD
Salmeterol—CYP3A5—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00124	0.0152	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00122	0.015	CbGpPWpGaD
Salmeterol—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00109	0.0134	CbGpPWpGaD
Salmeterol—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00108	0.0132	CbGpPWpGaD
Salmeterol—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00107	0.0132	CbGpPWpGaD
Salmeterol—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00102	0.0125	CbGpPWpGaD
Salmeterol—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00102	0.0125	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—GSTZ1—urinary bladder cancer	0.000961	0.0118	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000948	0.0116	CbGpPWpGaD
Salmeterol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000922	0.0113	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—GSTO2—urinary bladder cancer	0.000911	0.0112	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—NAT1—urinary bladder cancer	0.000911	0.0112	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000899	0.011	CbGpPWpGaD
Salmeterol—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000884	0.0108	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—UGT2B7—urinary bladder cancer	0.000833	0.0102	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000822	0.0101	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—CYP4B1—urinary bladder cancer	0.00075	0.0092	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00074	0.00907	CbGpPWpGaD
Salmeterol—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000714	0.00139	CcSEcCtD
Salmeterol—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000711	0.00139	CcSEcCtD
Salmeterol—Fatigue—Gemcitabine—urinary bladder cancer	0.000711	0.00139	CcSEcCtD
Salmeterol—Constipation—Gemcitabine—urinary bladder cancer	0.000705	0.00138	CcSEcCtD
Salmeterol—Pain—Gemcitabine—urinary bladder cancer	0.000705	0.00138	CcSEcCtD
Salmeterol—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000704	0.00137	CcSEcCtD
Salmeterol—Asthenia—Thiotepa—urinary bladder cancer	0.000703	0.00137	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.0007	0.00137	CcSEcCtD
Salmeterol—Infection—Etoposide—urinary bladder cancer	0.000699	0.00137	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.000695	0.00852	CbGpPWpGaD
Salmeterol—Influenza—Epirubicin—urinary bladder cancer	0.000694	0.00135	CcSEcCtD
Salmeterol—Asthma—Epirubicin—urinary bladder cancer	0.000694	0.00135	CcSEcCtD
Salmeterol—Pain—Fluorouracil—urinary bladder cancer	0.000693	0.00135	CcSEcCtD
Salmeterol—Paraesthesia—Cisplatin—urinary bladder cancer	0.00069	0.00135	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000689	0.00135	CcSEcCtD
Salmeterol—Tachycardia—Etoposide—urinary bladder cancer	0.000687	0.00134	CcSEcCtD
Salmeterol—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000685	0.0084	CbGpPWpGaD
Salmeterol—Dyspnoea—Cisplatin—urinary bladder cancer	0.000685	0.00134	CcSEcCtD
Salmeterol—Skin disorder—Etoposide—urinary bladder cancer	0.000684	0.00133	CcSEcCtD
Salmeterol—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000679	0.00133	CcSEcCtD
Salmeterol—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000679	0.00132	CcSEcCtD
Salmeterol—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000671	0.00823	CbGpPWpGaD
Salmeterol—Diarrhoea—Thiotepa—urinary bladder cancer	0.000671	0.00131	CcSEcCtD
Salmeterol—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000668	0.0013	CcSEcCtD
Salmeterol—Bronchitis—Epirubicin—urinary bladder cancer	0.000667	0.0013	CcSEcCtD
Salmeterol—Pneumonia—Methotrexate—urinary bladder cancer	0.000665	0.0013	CcSEcCtD
Salmeterol—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000664	0.0013	CcSEcCtD
Salmeterol—Infestation—Methotrexate—urinary bladder cancer	0.000661	0.00129	CcSEcCtD
Salmeterol—Infestation NOS—Methotrexate—urinary bladder cancer	0.000661	0.00129	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.000659	0.00807	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.000659	0.00807	CbGpPWpGaD
Salmeterol—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000658	0.00806	CbGpPWpGaD
Salmeterol—Pain—Cisplatin—urinary bladder cancer	0.000657	0.00128	CcSEcCtD
Salmeterol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000652	0.00127	CcSEcCtD
Salmeterol—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000649	0.00796	CbGpPWpGaD
Salmeterol—Dizziness—Thiotepa—urinary bladder cancer	0.000648	0.00126	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000645	0.00126	CcSEcCtD
Salmeterol—Urticaria—Fluorouracil—urinary bladder cancer	0.000644	0.00126	CcSEcCtD
Salmeterol—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000643	0.00125	CcSEcCtD
Salmeterol—Influenza—Doxorubicin—urinary bladder cancer	0.000642	0.00125	CcSEcCtD
Salmeterol—Asthma—Doxorubicin—urinary bladder cancer	0.000642	0.00125	CcSEcCtD
Salmeterol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000641	0.00125	CcSEcCtD
Salmeterol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000633	0.00124	CcSEcCtD
Salmeterol—Paraesthesia—Etoposide—urinary bladder cancer	0.000632	0.00123	CcSEcCtD
Salmeterol—Dyspnoea—Etoposide—urinary bladder cancer	0.000628	0.00123	CcSEcCtD
Salmeterol—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000626	0.00122	CcSEcCtD
Salmeterol—Epistaxis—Methotrexate—urinary bladder cancer	0.000624	0.00122	CcSEcCtD
Salmeterol—Vomiting—Thiotepa—urinary bladder cancer	0.000623	0.00122	CcSEcCtD
Salmeterol—Pneumonia—Epirubicin—urinary bladder cancer	0.000622	0.00121	CcSEcCtD
Salmeterol—Infestation NOS—Epirubicin—urinary bladder cancer	0.000619	0.00121	CcSEcCtD
Salmeterol—Infestation—Epirubicin—urinary bladder cancer	0.000619	0.00121	CcSEcCtD
Salmeterol—Rash—Thiotepa—urinary bladder cancer	0.000618	0.00121	CcSEcCtD
Salmeterol—Bronchitis—Doxorubicin—urinary bladder cancer	0.000618	0.00121	CcSEcCtD
Salmeterol—Dermatitis—Thiotepa—urinary bladder cancer	0.000617	0.0012	CcSEcCtD
Salmeterol—Headache—Thiotepa—urinary bladder cancer	0.000614	0.0012	CcSEcCtD
Salmeterol—Body temperature increased—Cisplatin—urinary bladder cancer	0.000607	0.00119	CcSEcCtD
Salmeterol—Fatigue—Etoposide—urinary bladder cancer	0.000607	0.00118	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.000602	0.00738	CbGpPWpGaD
Salmeterol—Pain—Etoposide—urinary bladder cancer	0.000602	0.00118	CcSEcCtD
Salmeterol—Constipation—Etoposide—urinary bladder cancer	0.000602	0.00118	CcSEcCtD
Salmeterol—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.000602	0.00738	CbGpPWpGaD
Salmeterol—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000601	0.00117	CcSEcCtD
Salmeterol—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000601	0.00117	CcSEcCtD
Salmeterol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000597	0.00117	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000597	0.00116	CcSEcCtD
Salmeterol—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000594	0.00728	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000593	0.00728	CbGpPWpGaD
Salmeterol—Asthenia—Gemcitabine—urinary bladder cancer	0.000592	0.00115	CcSEcCtD
Salmeterol—Pharyngitis—Methotrexate—urinary bladder cancer	0.000589	0.00115	CcSEcCtD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000585	0.00718	CbGpPWpGaD
Salmeterol—Epistaxis—Epirubicin—urinary bladder cancer	0.000584	0.00114	CcSEcCtD
Salmeterol—Nausea—Thiotepa—urinary bladder cancer	0.000582	0.00114	CcSEcCtD
Salmeterol—Sinusitis—Epirubicin—urinary bladder cancer	0.000581	0.00113	CcSEcCtD
Salmeterol—Feeling abnormal—Etoposide—urinary bladder cancer	0.00058	0.00113	CcSEcCtD
Salmeterol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000579	0.00113	CcSEcCtD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000578	0.00708	CbGpPWpGaD
Salmeterol—Pneumonia—Doxorubicin—urinary bladder cancer	0.000576	0.00112	CcSEcCtD
Salmeterol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000576	0.00112	CcSEcCtD
Salmeterol—Infestation—Doxorubicin—urinary bladder cancer	0.000573	0.00112	CcSEcCtD
Salmeterol—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000573	0.00112	CcSEcCtD
Salmeterol—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.00057	0.00699	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.00057	0.00699	CbGpPWpGaD
Salmeterol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000566	0.00111	CcSEcCtD
Salmeterol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000564	0.0011	CcSEcCtD
Salmeterol—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000563	0.0069	CbGpPWpGaD
Salmeterol—Urticaria—Etoposide—urinary bladder cancer	0.000559	0.00109	CcSEcCtD
Salmeterol—Rhinitis—Epirubicin—urinary bladder cancer	0.000557	0.00109	CcSEcCtD
Salmeterol—Body temperature increased—Etoposide—urinary bladder cancer	0.000557	0.00109	CcSEcCtD
Salmeterol—Abdominal pain—Etoposide—urinary bladder cancer	0.000557	0.00109	CcSEcCtD
Salmeterol—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000557	0.00109	CcSEcCtD
Salmeterol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000557	0.00109	CcSEcCtD
Salmeterol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000555	0.00108	CcSEcCtD
Salmeterol—Asthenia—Cisplatin—urinary bladder cancer	0.000551	0.00108	CcSEcCtD
Salmeterol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000551	0.00108	CcSEcCtD
Salmeterol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000551	0.00108	CcSEcCtD
Salmeterol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000546	0.00107	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.000542	0.00665	CbGpPWpGaD
Salmeterol—Epistaxis—Doxorubicin—urinary bladder cancer	0.00054	0.00105	CcSEcCtD
Salmeterol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000537	0.00105	CcSEcCtD
Salmeterol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000536	0.00105	CcSEcCtD
Salmeterol—Dizziness—Fluorouracil—urinary bladder cancer	0.000536	0.00105	CcSEcCtD
Salmeterol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000535	0.00104	CcSEcCtD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000535	0.00656	CbGpPWpGaD
Salmeterol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000526	0.00103	CcSEcCtD
Salmeterol—Vomiting—Gemcitabine—urinary bladder cancer	0.000524	0.00102	CcSEcCtD
Salmeterol—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.000522	0.0064	CbGpPWpGaD
Salmeterol—Mental disorder—Methotrexate—urinary bladder cancer	0.00052	0.00101	CcSEcCtD
Salmeterol—Rash—Gemcitabine—urinary bladder cancer	0.00052	0.00101	CcSEcCtD
Salmeterol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000519	0.00101	CcSEcCtD
Salmeterol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000519	0.00101	CcSEcCtD
Salmeterol—Malnutrition—Methotrexate—urinary bladder cancer	0.000517	0.00101	CcSEcCtD
Salmeterol—Headache—Gemcitabine—urinary bladder cancer	0.000516	0.00101	CcSEcCtD
Salmeterol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000516	0.00101	CcSEcCtD
Salmeterol—Vomiting—Fluorouracil—urinary bladder cancer	0.000515	0.00101	CcSEcCtD
Salmeterol—Rhinitis—Doxorubicin—urinary bladder cancer	0.000515	0.00101	CcSEcCtD
Salmeterol—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000515	0.00631	CbGpPWpGaD
Salmeterol—Rash—Fluorouracil—urinary bladder cancer	0.000511	0.000998	CcSEcCtD
Salmeterol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000511	0.000997	CcSEcCtD
Salmeterol—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00051	0.000996	CcSEcCtD
Salmeterol—Headache—Fluorouracil—urinary bladder cancer	0.000508	0.000991	CcSEcCtD
Salmeterol—Asthenia—Etoposide—urinary bladder cancer	0.000505	0.000986	CcSEcCtD
Salmeterol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000505	0.000986	CcSEcCtD
Salmeterol—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000504	0.00618	CbGpPWpGaD
Salmeterol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000502	0.000979	CcSEcCtD
Salmeterol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000501	0.000977	CcSEcCtD
Salmeterol—Back pain—Methotrexate—urinary bladder cancer	0.0005	0.000975	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—NAT2—urinary bladder cancer	0.000499	0.00612	CbGpPWpGaD
Salmeterol—Arrhythmia—Epirubicin—urinary bladder cancer	0.000496	0.000968	CcSEcCtD
Salmeterol—CYP3A7—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000492	0.00604	CbGpPWpGaD
Salmeterol—Nausea—Gemcitabine—urinary bladder cancer	0.00049	0.000956	CcSEcCtD
Salmeterol—Vomiting—Cisplatin—urinary bladder cancer	0.000489	0.000954	CcSEcCtD
Salmeterol—ADRB2—Arf6 trafficking events—CDH1—urinary bladder cancer	0.000488	0.00599	CbGpPWpGaD
Salmeterol—Mental disorder—Epirubicin—urinary bladder cancer	0.000487	0.00095	CcSEcCtD
Salmeterol—Rash—Cisplatin—urinary bladder cancer	0.000485	0.000946	CcSEcCtD
Salmeterol—Dermatitis—Cisplatin—urinary bladder cancer	0.000484	0.000945	CcSEcCtD
Salmeterol—Malnutrition—Epirubicin—urinary bladder cancer	0.000484	0.000944	CcSEcCtD
Salmeterol—Diarrhoea—Etoposide—urinary bladder cancer	0.000482	0.00094	CcSEcCtD
Salmeterol—Nausea—Fluorouracil—urinary bladder cancer	0.000482	0.00094	CcSEcCtD
Salmeterol—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000479	0.000936	CcSEcCtD
Salmeterol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000477	0.000931	CcSEcCtD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000475	0.00582	CbGpPWpGaD
Salmeterol—Tension—Epirubicin—urinary bladder cancer	0.000475	0.000926	CcSEcCtD
Salmeterol—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000473	0.0058	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.00047	0.00576	CbGpPWpGaD
Salmeterol—Nervousness—Epirubicin—urinary bladder cancer	0.00047	0.000917	CcSEcCtD
Salmeterol—Back pain—Epirubicin—urinary bladder cancer	0.000468	0.000913	CcSEcCtD
Salmeterol—Malaise—Methotrexate—urinary bladder cancer	0.000466	0.000909	CcSEcCtD
Salmeterol—Dizziness—Etoposide—urinary bladder cancer	0.000466	0.000909	CcSEcCtD
Salmeterol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000465	0.000907	CcSEcCtD
Salmeterol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000464	0.000906	CcSEcCtD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000463	0.00568	CbGpPWpGaD
Salmeterol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000463	0.000904	CcSEcCtD
Salmeterol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000459	0.000896	CcSEcCtD
Salmeterol—Nausea—Cisplatin—urinary bladder cancer	0.000456	0.000891	CcSEcCtD
Salmeterol—Cough—Methotrexate—urinary bladder cancer	0.000451	0.00088	CcSEcCtD
Salmeterol—Mental disorder—Doxorubicin—urinary bladder cancer	0.00045	0.000879	CcSEcCtD
Salmeterol—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000449	0.000876	CcSEcCtD
Salmeterol—Vomiting—Etoposide—urinary bladder cancer	0.000448	0.000874	CcSEcCtD
Salmeterol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000447	0.000873	CcSEcCtD
Salmeterol—Agitation—Epirubicin—urinary bladder cancer	0.000444	0.000867	CcSEcCtD
Salmeterol—Rash—Etoposide—urinary bladder cancer	0.000444	0.000866	CcSEcCtD
Salmeterol—Dermatitis—Etoposide—urinary bladder cancer	0.000443	0.000866	CcSEcCtD
Salmeterol—Headache—Etoposide—urinary bladder cancer	0.000441	0.000861	CcSEcCtD
Salmeterol—Chest pain—Methotrexate—urinary bladder cancer	0.00044	0.000859	CcSEcCtD
Salmeterol—Arthralgia—Methotrexate—urinary bladder cancer	0.00044	0.000859	CcSEcCtD
Salmeterol—Myalgia—Methotrexate—urinary bladder cancer	0.00044	0.000859	CcSEcCtD
Salmeterol—Tension—Doxorubicin—urinary bladder cancer	0.000439	0.000857	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000437	0.000853	CcSEcCtD
Salmeterol—Malaise—Epirubicin—urinary bladder cancer	0.000436	0.000851	CcSEcCtD
Salmeterol—Discomfort—Methotrexate—urinary bladder cancer	0.000435	0.000848	CcSEcCtD
Salmeterol—Nervousness—Doxorubicin—urinary bladder cancer	0.000435	0.000848	CcSEcCtD
Salmeterol—Back pain—Doxorubicin—urinary bladder cancer	0.000433	0.000845	CcSEcCtD
Salmeterol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00043	0.00084	CcSEcCtD
Salmeterol—Palpitations—Epirubicin—urinary bladder cancer	0.000427	0.000834	CcSEcCtD
Salmeterol—Cough—Epirubicin—urinary bladder cancer	0.000422	0.000824	CcSEcCtD
Salmeterol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000422	0.000823	CcSEcCtD
Salmeterol—Infection—Methotrexate—urinary bladder cancer	0.000419	0.000818	CcSEcCtD
Salmeterol—Nausea—Etoposide—urinary bladder cancer	0.000418	0.000816	CcSEcCtD
Salmeterol—Hypertension—Epirubicin—urinary bladder cancer	0.000417	0.000815	CcSEcCtD
Salmeterol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000415	0.00081	CcSEcCtD
Salmeterol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000414	0.000807	CcSEcCtD
Salmeterol—ADRB2—Arf6 signaling events—SRC—urinary bladder cancer	0.000412	0.00506	CbGpPWpGaD
Salmeterol—Chest pain—Epirubicin—urinary bladder cancer	0.000412	0.000803	CcSEcCtD
Salmeterol—Myalgia—Epirubicin—urinary bladder cancer	0.000412	0.000803	CcSEcCtD
Salmeterol—Arthralgia—Epirubicin—urinary bladder cancer	0.000412	0.000803	CcSEcCtD
Salmeterol—Agitation—Doxorubicin—urinary bladder cancer	0.000411	0.000802	CcSEcCtD
Salmeterol—Anxiety—Epirubicin—urinary bladder cancer	0.00041	0.000801	CcSEcCtD
Salmeterol—Skin disorder—Methotrexate—urinary bladder cancer	0.00041	0.000799	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000409	0.000798	CcSEcCtD
Salmeterol—Discomfort—Epirubicin—urinary bladder cancer	0.000407	0.000794	CcSEcCtD
Salmeterol—Malaise—Doxorubicin—urinary bladder cancer	0.000403	0.000787	CcSEcCtD
Salmeterol—Dry mouth—Epirubicin—urinary bladder cancer	0.000403	0.000786	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—HPGDS—urinary bladder cancer	0.000399	0.00489	CbGpPWpGaD
Salmeterol—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000397	0.00487	CbGpPWpGaD
Salmeterol—Palpitations—Doxorubicin—urinary bladder cancer	0.000395	0.000772	CcSEcCtD
Salmeterol—Oedema—Epirubicin—urinary bladder cancer	0.000395	0.00077	CcSEcCtD
Salmeterol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000395	0.00077	CcSEcCtD
Salmeterol—Infection—Epirubicin—urinary bladder cancer	0.000392	0.000765	CcSEcCtD
Salmeterol—Cough—Doxorubicin—urinary bladder cancer	0.00039	0.000762	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—GSTT1—urinary bladder cancer	0.000387	0.00475	CbGpPWpGaD
Salmeterol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000387	0.000755	CcSEcCtD
Salmeterol—Hypertension—Doxorubicin—urinary bladder cancer	0.000386	0.000754	CcSEcCtD
Salmeterol—Tachycardia—Epirubicin—urinary bladder cancer	0.000385	0.000752	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000384	0.00075	CcSEcCtD
Salmeterol—Skin disorder—Epirubicin—urinary bladder cancer	0.000383	0.000748	CcSEcCtD
Salmeterol—Insomnia—Methotrexate—urinary bladder cancer	0.000381	0.000744	CcSEcCtD
Salmeterol—Chest pain—Doxorubicin—urinary bladder cancer	0.000381	0.000743	CcSEcCtD
Salmeterol—Arthralgia—Doxorubicin—urinary bladder cancer	0.000381	0.000743	CcSEcCtD
Salmeterol—Myalgia—Doxorubicin—urinary bladder cancer	0.000381	0.000743	CcSEcCtD
Salmeterol—Anxiety—Doxorubicin—urinary bladder cancer	0.00038	0.000741	CcSEcCtD
Salmeterol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000379	0.000739	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000378	0.000738	CcSEcCtD
Salmeterol—Discomfort—Doxorubicin—urinary bladder cancer	0.000376	0.000735	CcSEcCtD
Salmeterol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000376	0.000734	CcSEcCtD
Salmeterol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000373	0.000727	CcSEcCtD
Salmeterol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000371	0.000724	CcSEcCtD
Salmeterol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000365	0.000713	CcSEcCtD
Salmeterol—Oedema—Doxorubicin—urinary bladder cancer	0.000365	0.000713	CcSEcCtD
Salmeterol—Fatigue—Methotrexate—urinary bladder cancer	0.000364	0.00071	CcSEcCtD
Salmeterol—Infection—Doxorubicin—urinary bladder cancer	0.000363	0.000708	CcSEcCtD
Salmeterol—ADRB2—Arf6 signaling events—EGFR—urinary bladder cancer	0.000361	0.00443	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000361	0.00442	CbGpPWpGaD
Salmeterol—Pain—Methotrexate—urinary bladder cancer	0.000361	0.000704	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00036	0.000702	CcSEcCtD
Salmeterol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000358	0.000699	CcSEcCtD
Salmeterol—Insomnia—Epirubicin—urinary bladder cancer	0.000357	0.000697	CcSEcCtD
Salmeterol—Tachycardia—Doxorubicin—urinary bladder cancer	0.000356	0.000696	CcSEcCtD
Salmeterol—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000356	0.00436	CbGpPWpGaD
Salmeterol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000355	0.000692	CcSEcCtD
Salmeterol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000354	0.000692	CcSEcCtD
Salmeterol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000352	0.000687	CcSEcCtD
Salmeterol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000348	0.000678	CcSEcCtD
Salmeterol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000347	0.000678	CcSEcCtD
Salmeterol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000345	0.000673	CcSEcCtD
Salmeterol—Fatigue—Epirubicin—urinary bladder cancer	0.00034	0.000664	CcSEcCtD
Salmeterol—Pain—Epirubicin—urinary bladder cancer	0.000337	0.000659	CcSEcCtD
Salmeterol—Constipation—Epirubicin—urinary bladder cancer	0.000337	0.000659	CcSEcCtD
Salmeterol—Urticaria—Methotrexate—urinary bladder cancer	0.000335	0.000654	CcSEcCtD
Salmeterol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000333	0.000651	CcSEcCtD
Salmeterol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000333	0.000651	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000333	0.000649	CcSEcCtD
Salmeterol—Insomnia—Doxorubicin—urinary bladder cancer	0.00033	0.000645	CcSEcCtD
Salmeterol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000328	0.00064	CcSEcCtD
Salmeterol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000326	0.000635	CcSEcCtD
Salmeterol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000325	0.000635	CcSEcCtD
Salmeterol—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000323	0.00396	CbGpPWpGaD
Salmeterol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000323	0.00063	CcSEcCtD
Salmeterol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000321	0.000627	CcSEcCtD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000319	0.00391	CbGpPWpGaD
Salmeterol—Fatigue—Doxorubicin—urinary bladder cancer	0.000315	0.000614	CcSEcCtD
Salmeterol—Urticaria—Epirubicin—urinary bladder cancer	0.000314	0.000612	CcSEcCtD
Salmeterol—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000313	0.00383	CbGpPWpGaD
Salmeterol—Constipation—Doxorubicin—urinary bladder cancer	0.000312	0.000609	CcSEcCtD
Salmeterol—Pain—Doxorubicin—urinary bladder cancer	0.000312	0.000609	CcSEcCtD
Salmeterol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000312	0.000609	CcSEcCtD
Salmeterol—Abdominal pain—Epirubicin—urinary bladder cancer	0.000312	0.000609	CcSEcCtD
Salmeterol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000311	0.000606	CcSEcCtD
Salmeterol—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000308	0.00378	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000306	0.00375	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000306	0.00375	CbGpPWpGaD
Salmeterol—Asthenia—Methotrexate—urinary bladder cancer	0.000303	0.000591	CcSEcCtD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000302	0.0037	CbGpPWpGaD
Salmeterol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000301	0.000587	CcSEcCtD
Salmeterol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000299	0.000583	CcSEcCtD
Salmeterol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000291	0.000567	CcSEcCtD
Salmeterol—Urticaria—Doxorubicin—urinary bladder cancer	0.00029	0.000566	CcSEcCtD
Salmeterol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000289	0.000563	CcSEcCtD
Salmeterol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000289	0.000563	CcSEcCtD
Salmeterol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000289	0.000563	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000288	0.00354	CbGpPWpGaD
Salmeterol—Asthenia—Epirubicin—urinary bladder cancer	0.000283	0.000553	CcSEcCtD
Salmeterol—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00028	0.00343	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.00028	0.00343	CbGpPWpGaD
Salmeterol—Dizziness—Methotrexate—urinary bladder cancer	0.000279	0.000544	CcSEcCtD
Salmeterol—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000276	0.00339	CbGpPWpGaD
Salmeterol—Diarrhoea—Epirubicin—urinary bladder cancer	0.00027	0.000527	CcSEcCtD
Salmeterol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000269	0.000525	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—GSTP1—urinary bladder cancer	0.000268	0.00329	CbGpPWpGaD
Salmeterol—Vomiting—Methotrexate—urinary bladder cancer	0.000268	0.000523	CcSEcCtD
Salmeterol—Rash—Methotrexate—urinary bladder cancer	0.000266	0.000519	CcSEcCtD
Salmeterol—Dermatitis—Methotrexate—urinary bladder cancer	0.000266	0.000518	CcSEcCtD
Salmeterol—CYP3A7—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000265	0.00324	CbGpPWpGaD
Salmeterol—Headache—Methotrexate—urinary bladder cancer	0.000264	0.000516	CcSEcCtD
Salmeterol—Asthenia—Doxorubicin—urinary bladder cancer	0.000262	0.000511	CcSEcCtD
Salmeterol—Dizziness—Epirubicin—urinary bladder cancer	0.000261	0.000509	CcSEcCtD
Salmeterol—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000252	0.00309	CbGpPWpGaD
Salmeterol—Vomiting—Epirubicin—urinary bladder cancer	0.000251	0.00049	CcSEcCtD
Salmeterol—Nausea—Methotrexate—urinary bladder cancer	0.00025	0.000489	CcSEcCtD
Salmeterol—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.00025	0.00306	CbGpPWpGaD
Salmeterol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00025	0.000488	CcSEcCtD
Salmeterol—Rash—Epirubicin—urinary bladder cancer	0.000249	0.000486	CcSEcCtD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000249	0.00305	CbGpPWpGaD
Salmeterol—Dermatitis—Epirubicin—urinary bladder cancer	0.000249	0.000485	CcSEcCtD
Salmeterol—Headache—Epirubicin—urinary bladder cancer	0.000247	0.000483	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—GSTM1—urinary bladder cancer	0.000247	0.00302	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000243	0.00298	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000242	0.00297	CbGpPWpGaD
Salmeterol—Dizziness—Doxorubicin—urinary bladder cancer	0.000241	0.000471	CcSEcCtD
Salmeterol—Nausea—Epirubicin—urinary bladder cancer	0.000234	0.000458	CcSEcCtD
Salmeterol—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000234	0.00287	CbGpPWpGaD
Salmeterol—Vomiting—Doxorubicin—urinary bladder cancer	0.000232	0.000453	CcSEcCtD
Salmeterol—Rash—Doxorubicin—urinary bladder cancer	0.00023	0.000449	CcSEcCtD
Salmeterol—Dermatitis—Doxorubicin—urinary bladder cancer	0.00023	0.000449	CcSEcCtD
Salmeterol—Headache—Doxorubicin—urinary bladder cancer	0.000229	0.000446	CcSEcCtD
Salmeterol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000217	0.00266	CbGpPWpGaD
Salmeterol—Nausea—Doxorubicin—urinary bladder cancer	0.000217	0.000423	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000194	0.00238	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000191	0.00235	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00018	0.00221	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000178	0.00219	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000176	0.00216	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000168	0.00206	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000168	0.00206	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000166	0.00203	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000165	0.00203	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	0.000164	0.00202	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	0.000156	0.00191	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NAT1—urinary bladder cancer	0.000156	0.00191	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000154	0.00189	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000152	0.00187	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	0.000142	0.00175	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000134	0.00164	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.00013	0.00159	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	0.000128	0.00157	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	0.000121	0.00149	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000119	0.00146	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	0.000118	0.00145	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000113	0.00138	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000113	0.00138	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.000103	0.00126	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	0.000103	0.00126	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	9.75e-05	0.0012	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NAT1—urinary bladder cancer	9.75e-05	0.0012	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HDAC4—urinary bladder cancer	9.67e-05	0.00119	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.59e-05	0.00118	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TYMP—urinary bladder cancer	9.44e-05	0.00116	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	9.27e-05	0.00114	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	9.02e-05	0.00111	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	8.92e-05	0.00109	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.89e-05	0.00109	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	8.76e-05	0.00107	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	8.57e-05	0.00105	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NAT2—urinary bladder cancer	8.54e-05	0.00105	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	8.54e-05	0.00105	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	8.29e-05	0.00102	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.17e-05	0.001	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GLI1—urinary bladder cancer	8.1e-05	0.000993	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	8.03e-05	0.000985	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	7.59e-05	0.00093	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	7.39e-05	0.000906	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—RRM2—urinary bladder cancer	7.37e-05	0.000903	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	6.82e-05	0.000837	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ENO2—urinary bladder cancer	6.82e-05	0.000837	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TYMP—urinary bladder cancer	6.82e-05	0.000837	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	6.62e-05	0.000812	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CXCL8—urinary bladder cancer	6.53e-05	0.0008	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NAT2—urinary bladder cancer	6.17e-05	0.000757	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.93e-05	0.000727	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TYMP—urinary bladder cancer	5.91e-05	0.000725	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.68e-05	0.000696	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RBX1—urinary bladder cancer	5.55e-05	0.000681	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.52e-05	0.000677	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NQO1—urinary bladder cancer	5.5e-05	0.000674	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NAT2—urinary bladder cancer	5.34e-05	0.000655	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—RRM2—urinary bladder cancer	5.33e-05	0.000653	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.24e-05	0.000642	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.24e-05	0.000642	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TSC1—urinary bladder cancer	5.22e-05	0.00064	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JAG1—urinary bladder cancer	4.97e-05	0.000609	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.93e-05	0.000605	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.93e-05	0.000605	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.79e-05	0.000587	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.78e-05	0.000587	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—RRM2—urinary bladder cancer	4.61e-05	0.000566	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	4.59e-05	0.000563	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.31e-05	0.000529	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	4.27e-05	0.000524	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ENO2—urinary bladder cancer	4.27e-05	0.000524	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TYMS—urinary bladder cancer	4.27e-05	0.000523	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.25e-05	0.000521	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	4.22e-05	0.000517	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	4.22e-05	0.000517	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—RHOA—urinary bladder cancer	4.2e-05	0.000515	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	4.14e-05	0.000508	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.08e-05	0.0005	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.07e-05	0.000499	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GPX1—urinary bladder cancer	4.04e-05	0.000495	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—S100B—urinary bladder cancer	4.02e-05	0.000493	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.98e-05	0.000488	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.97e-05	0.000487	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3.96e-05	0.000486	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—RHOA—urinary bladder cancer	3.81e-05	0.000468	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	3.73e-05	0.000457	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.69e-05	0.000452	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NCOR1—urinary bladder cancer	3.62e-05	0.000444	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—IL2—urinary bladder cancer	3.52e-05	0.000432	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.44e-05	0.000422	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL8—urinary bladder cancer	3.35e-05	0.000411	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.34e-05	0.00041	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	3.32e-05	0.000407	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2—urinary bladder cancer	3.2e-05	0.000392	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TERT—urinary bladder cancer	3.19e-05	0.000391	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.17e-05	0.000389	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TYMS—urinary bladder cancer	3.08e-05	0.000378	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	3.05e-05	0.000374	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	3.05e-05	0.000374	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARG—urinary bladder cancer	3.02e-05	0.00037	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGFR3—urinary bladder cancer	2.93e-05	0.000359	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.92e-05	0.000358	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.91e-05	0.000357	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.9e-05	0.000356	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.87e-05	0.000352	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.87e-05	0.000352	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.87e-05	0.000351	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ESR1—urinary bladder cancer	2.84e-05	0.000348	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.78e-05	0.000341	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.69e-05	0.00033	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.67e-05	0.000327	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.64e-05	0.000324	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.64e-05	0.000324	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.53e-05	0.00031	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	2.49e-05	0.000305	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.48e-05	0.000304	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.48e-05	0.000304	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	2.46e-05	0.000302	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	2.45e-05	0.0003	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	2.38e-05	0.000291	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.33e-05	0.000286	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	2.31e-05	0.000284	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.29e-05	0.000281	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.29e-05	0.000281	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	2.25e-05	0.000276	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.22e-05	0.000273	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.18e-05	0.000268	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2.1e-05	0.000257	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	2.09e-05	0.000256	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTEN—urinary bladder cancer	2.07e-05	0.000254	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	1.98e-05	0.000243	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.98e-05	0.000242	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	1.97e-05	0.000241	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.89e-05	0.000232	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	1.89e-05	0.000232	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.85e-05	0.000227	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	1.84e-05	0.000226	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.82e-05	0.000223	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	1.79e-05	0.000219	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.78e-05	0.000219	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	1.78e-05	0.000218	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.72e-05	0.000211	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	1.7e-05	0.000208	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	1.65e-05	0.000202	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.54e-05	0.000189	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.5e-05	0.000184	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.49e-05	0.000182	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	1.48e-05	0.000181	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	1.45e-05	0.000177	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.43e-05	0.000176	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.43e-05	0.000175	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.42e-05	0.000174	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.42e-05	0.000174	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	1.37e-05	0.000167	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.36e-05	0.000166	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.33e-05	0.000163	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.3e-05	0.000159	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.25e-05	0.000154	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.24e-05	0.000152	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	1.21e-05	0.000149	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	1.16e-05	0.000142	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.02e-05	0.000124	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.75e-06	0.00012	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.99e-06	9.79e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.97e-06	8.54e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.64e-06	8.15e-05	CbGpPWpGaD
